过氧化物酶体增殖物激活受体双通道与心血管并发症

Influence of PPAR Dual Agonists and Cardiovascular Complications

心血管疾病是糖尿病患者的主要死亡原因,过氧化物酶体增殖物激活受体(peroxisome proliferator-activated receptors,PPARs)是核受体超家族中的一个成员,分为PPARα、PPARδ及PPARγ三种类型。PPARα、γ双重激动剂是一类新的药物,与不同的配体结合激活PPARα和PPARγ受体,进而控制糖尿病和具有心血管保护作用。许多研究正在针对PPARα、δ和PPARδ、γ双通道激动剂和PPARα、δ、γ全通道激动剂,研究其对预防糖尿病患者并发心血管疾病的作用。

Cardiovascular disorders are the major cause of mortality in patients of diabetes mellitus.Peroxisome proliferator activated receptors（PPARs） are ligand-activated transcription factors of the nuclear hormone receptor superfamily comprising three subtypes： PPAR-α,PPAR-δ and PPAR-γ.The PPARα/γ dual agonists were developed to increase insulin sensitivity and simultaneously prevent diabetic cardiovascular complications.Further studies are on track to develop PPARα/δ and PPAR/γ dual agonists and PPARα/δ/γ pan agonists for the treatment of diabetic cardiovascular complications.This review analyzes the protective and detrimental effect of PPAR agonists in diabetic cardiovascular complications.